ArticleDermatology reports2023
Generalized morphea induced by the COVID-19 vaccine in a patient with chronic urticaria.
Article in Dermatology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse events following vaccinations have been noted for centuries, but as of recently, discussions concerning these adverse effects have increased due to the COVID-19 pandemic and the consequent delivery of vaccinations. Through presenting new cases of such adverse events and reviewing the literature, we aim to facilitate the recognition of COVID-19 vaccine-induced autoimmune diseases that may occur in the years after the pandemic has been contained. We report on a case of biopsy-proven morphea after the COVID-19 vaccine, in which case the patient developed diffuse skin lesions all over her body. The patient was known to have chronic urticaria and received two doses of the Pfizer-BioNTech COVID-19 vaccines (BioNTech, Fosun Pharma, Pfizer, New York City, USA). The patient started to notice itchy lesions on her arms two months after taking her second dose of the vaccine. This is the first case reported of generalized morphea following COVID-19 vaccination with another autoimmune disease and represents the first case of generalized morphea reported in the Middle East.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.